Search
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalOnce bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold.
Products: ARIXTRA 10 MG/0.8 ML S.C. ENJEKSIYONLUK COZELTI ICEREN KULLANIMA HAZIR SIRINGA, 10 ADET, ARIXTRA 2.5 MG/0.5 ML ENJEKSIYONLUK SOL.10 KUL.HAZ.SIRINGAAlprostadil
go.drugbank.com/drugs/DB00770ApprovedInvestigationalThis drug causes vasodilation by directly affecting vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth.
Synonyms: PGE-1, (11α,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acidProducts: CAVERJECT POWDER FOR INJECTION 10 mcg/ml, Caverject Dual 10 µg - ZweikammerzylinderampullenMannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalOn October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for … this indication under the name BRONCHITOL® by Chiesi USA Inc.
Mixtures: Sag-M, OSMOFUNDIN INJECTION 20%Products: % 10 MANNITOL SOLÜSYONU, 500 ML SETLI, % 10 MANNITOL SOLÜSYONU, 500 ML SETSIZImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalBrian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Categories: Heterocyclic Compounds, 1-RingSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidideBenazepril
go.drugbank.com/drugs/DB00542ApprovedInvestigationalUpon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].
Mixtures: CİBADREX 10/12,5 MG FİLM TABLET, 28 ADET, CİBADREX 5/6,25 MG FİLM TABLET, 28 ADETProducts: CİBACEN 10 MG FİLM KAPLI TABLET, 28 ADET, CIBACEN 10Lercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Mixtures: ZANIPRESS 10 MG/10 MG FILM TABLET, 30 ADET, ZANIPRESS 10 MG/10 MG FILM TABLET, 90 ADETCategories: Heterocyclic Compounds, 1-RingNitrendipine
go.drugbank.com/drugs/DB01054ApprovedWithdrawnNitrendipine is a calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natri...
Mixtures: Baroprine 10 mg/20 mg Tabletten, Cenipres 10 mg/20 mg TablettenCategories: Heterocyclic Compounds, 1-RingPiroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its lon...
Categories: Heterocyclic Compounds, 1-RingProducts: Felden 10 mg - Kapseln, PROXIGEL 10 MGMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until
Products: MYFORTIC (180 MG ), MYFORTIC 180 MGOndansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawn[L5221] The FDA withdrew its approval for the use of all intravenous drug products containing more than 16 mg of ondansetron hydrochloride in a single dose, due to a high risk of QT prolongation. … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.
Products: ONZYD 4 MG AGIZDA DAGILAN 10 TABLET, ONZYD 8 MG AGIZDA DAGILAN 10 TABLET